Bio-Rad Laboratories reported second-quarter earnings of $2.62 per share, beating the Zacks Consensus Estimate of $2.34 per share by nearly 12%. This marks only the second time in four quarters the medical products company has surpassed earnings expectations. However, revenue of $651 million for the quarter ended June 2026 fell slightly short of estimates by 0.97%, though the company has topped revenue forecasts in three of the past four quarters. Year-ago revenue was $651.6 million. Bio-Rad shares have gained 10.5% year-to-date, slightly underperforming the S&P 500's 11% rise. The company currently holds a Zacks Rank of Hold, suggesting shares should perform in line with the market.

Bio-Rad Laboratories (NYSE:BIO) releases earnings results, beats estimates by $0.87 EPS. August 4, 2026 Key points. * Bio-Rad beat quarterly expectations: The company reported EPS of $2.62, exceeding the $1.75 consensus by $0.87, while revenue reached $651 million versus estimates of $623.99 million. * Shares declined despite the earnings beat: BIO fell $1.84 to $332.87, though it remained near its 12-month high of $343.12 and above both its 50-day and 200-day moving averages. * Analyst sentiment remains cautious: Bio-Rad has an average "Reduce" rating and a consensus price target of $303.33, while institutional investors own 65.24% of the company. * Five stocks we like better than Bio-Rad Laboratories. Bio-Rad Laboratories (NYSE:BIO - Get Free Report) released its earnings results on Tuesday. The medical research company reported $2.62 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.75 by $0.87, FiscalAI reports. Bio-Rad Laboratories had a return on equity of 3.56% and a net margin of 6.52%.The business had revenue of $651.00 million for the quarter, compared to analyst estimates of $623.99 million. Bio-Rad Laboratories price performance. BIO stock traded down $1.84 on Tuesday, reaching $332.87. 263,909 shares of the company's stock were exchanged, compared to its average volume of 329,369. The stock has a fifty day moving average of $300.29 and a 200-day moving average of $287.70. The firm has a market cap of $8.91 billion, a PE ratio of 54.84 and a beta of 1.06. The company has a quick ratio of 2.37, a current ratio of 3.21 and a debt-to-equity ratio of 0.12. Bio-Rad Laboratories has a twelve month low of $236.73 and a twelve month high of $343.12. Institutional investors weigh in on Bio-Rad Laboratories. Institutional investors have recently made changes to their positions in the stock. Geneos Wealth Management Inc. increased its holdings in shares of Bio-Rad Laboratories by 115.2% in the 2nd quarter. Geneos Wealth Management Inc. now owns 142 shares of the medical research company's stock valued at $34,000 after purchasing an additional 76 shares in the last quarter. Los Angeles Capital Management LLC acquired a new position in Bio-Rad Laboratories during the fourth quarter worth about $47,000. Itau Unibanco Holding S.A. increased its holdings in Bio-Rad Laboratories by 57.6% in the fourth quarter. Itau Unibanco Holding S.A. now owns 197 shares of the medical research company's stock valued at $60,000 after buying an additional 72 shares in the last quarter. State of Wyoming acquired a new stake in shares of Bio-Rad Laboratories in the 4th quarter worth approximately $74,000. Finally, Quarry LP increased its stake in Bio-Rad Laboratories by 131.5% in the 3rd quarter. Quarry LP now owns 287 shares of the medical research company's stock valued at $80,000 after purchasing an additional 163 shares in the last quarter. 65.24% of the stock is currently owned by hedge funds and other institutional investors. Wall Street analysts forecast growth. A number of equities analysts recently weighed in on BIO shares. Zacks Research lowered shares of Bio-Rad Laboratories from a "hold" rating to a "strong sell" rating in a research report on Monday, July 13th. Wells Fargo & Company reduced their target price on shares of Bio-Rad Laboratories from $320.00 to $290.00 and set an "equal weight" rating for the company in a research note on Friday, May 1st. Royal Bank Of Canada began coverage on shares of Bio-Rad Laboratories in a report on Friday, May 15th. They issued an "outperform" rating and a $320.00 target price on the stock. Citigroup lowered shares of Bio-Rad Laboratories from a "buy" rating to a "neutral" rating and dropped their price target for the stock from $375.00 to $300.00 in a research note on Tuesday, April 7th. Finally, Weiss Ratings cut shares of Bio-Rad Laboratories from a "sell (d+)" rating to a "sell (d)" rating in a report on Wednesday, May 6th. One investment analyst has rated the stock with a Buy rating, two have issued a Hold rating and two have given a Sell rating to the company's stock. According to data from MarketBeat.com, Bio-Rad Laboratories presently has an average rating of "Reduce" and a consensus target price of $303.33. Discover more MarketBeat Research Tools text messages MarketBeat All Access Bio-Rad Laboratories company profile. Bio-Rad Laboratories, Inc is a global provider of life science research and clinical diagnostic products. The company operates through two primary business segments: Life Science and Clinical Diagnostics. Within the Life Science segment, Bio-Rad offers instruments, reagents and consumables for protein analysis, cell biology, gene expression and other molecular biology applications. The Clinical Diagnostics segment supplies quality control products, blood-typing reagents and instruments, and molecular diagnostic assays used in blood screening, infectious disease testing and routine clinical laboratories. Founded in 1952 by David and Alice Schwartz and headquartered in Hercules, California, Bio-Rad has grown its footprint across the Americas, Europe, Asia-Pacific and other regions. Further reading. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. Before you consider Bio-Rad Laboratories, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bio-Rad Laboratories wasn't on the list. While Bio-Rad Laboratories currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys. With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Bio-Rad launches Vericheck ddPCR Kits compatible with QX700 platform for biopharma quality control and cell and gene therapy workflows. Bio-Rad Laboratories, Inc., a global leader in life science research and clinical diagnostics products, today announced the launch of the QX700 System-compatible Vericheck ddPCR Kit portfolio for critical quality control (QC) workflows in advanced cell and gene therapy development and other biopharma applications. The portfolio includes Vericheck ddPCR Mycoplasma Detection, Empty-Full Capsid, Replication Competent Lentivirus, CHO Residual DNA Quantification, and E. coli Residual DNA Quantification kits. The newly launched kits extend Bio-Rad's existing ddPCR platform portfolio to provide ready-to-use, application-focused validated kits for critical QC workflows in biopharma, including cell and gene therapy applications. Bio-Rad's QX700 platform enables seven-color multiplexing and capacity to process up to 384 reactions in around two and a half hours, with minimal input volume, continuous loading capability, and easy-to-use software for streamlined data interpretation. By combining the performance of the QX700 Systems with the Vericheck Kits, researchers can generate precise, reproducible, and faster results for product development and product safety and quality. In advanced therapeutic development and manufacturing, QC testing is critical to ensure the safety and effectiveness of the product. Providing developers with a complete and accessible solution for high-priority QC testing needs, the new Vericheck Kits provide validated workflows to improve confidence in vector characterization and contamination detection, including replication-competent virus testing and residual host cell DNA quantification. The expansion of its range of Vericheck ddPCR Kits offers validated workflows with unmatched precision and sensitivity, combined with the power of the QX700 platform, enabling scalable, streamlined workflows and faster time to actionable results, By expanding the power of its QX700 platform through the development of this new portfolio of Vericheck Kits, Bio-Rad is continuing its commitment to support development of safer and more efficient advanced therapeutic development and manufacturing." Stephen Kulisch, Vice President of Marketing, Digital Biology Group, Bio-Rad Be the first to rate this article